{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:10:08Z","timestamp":1765807808927,"version":"3.40.3"},"reference-count":147,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780444642585"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.pbr.2020.07.015","type":"book-chapter","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T05:32:35Z","timestamp":1597728755000},"page":"265-285","source":"Crossref","is-referenced-by-count":4,"title":["Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine"],"prefix":"10.1016","author":[{"given":"V\u00e9ronique","family":"Sgambato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/bs.pbr.2020.07.015_bb0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1474-4422(05)70119-8","article-title":"Striatal deformities of the hand and foot in Parkinson's disease","volume":"4","author":"Ashour","year":"2005","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","article-title":"Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease","volume":"27","author":"Ballanger","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0025","first-page":"240","article-title":"Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems","volume":"94","author":"Battaglia","year":"1989","journal-title":"NIDA Res. Monogr."},{"issue":"5998","key":"10.1016\/bs.pbr.2020.07.015_bb0030","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1193692","article-title":"miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants","volume":"329","author":"Baudry","year":"2010","journal-title":"Science"},{"issue":"Pt. 9","key":"10.1016\/bs.pbr.2020.07.015_bb0035","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/brain\/awv183","article-title":"Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate","volume":"138","author":"Beaudoin-Gobert","year":"2015","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neuroimage.2018.08.016","article-title":"Pathophysiology of levodopa-induced dyskinesia: insights from multimodal imaging and immunohistochemistry in non-human primates","volume":"183","author":"Beaudoin-Gobert","year":"2018","journal-title":"Neuroimage"},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0045","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding","volume":"379","author":"B\u00e9dard","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1460-9568.1993.tb00505.x","article-title":"Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys","volume":"5","author":"Benazzouz","year":"1993","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0055","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2402638","article-title":"Reversal of experimental parkinsonism by lesions of the subthalamic nucleus","volume":"249","author":"Bergman","year":"1990","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(97)00531-3","article-title":"A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey","volume":"766","author":"Bezard","year":"1997","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/bs.pbr.2020.07.015_bb0065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of L-DOPA-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"issue":"5","key":"10.1016\/bs.pbr.2020.07.015_bb0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.parkreldis.2004.02.011","article-title":"Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms","volume":"10","author":"Blanchet","year":"2004","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0075","doi-asserted-by":"crossref","first-page":"845618","DOI":"10.1155\/2012\/845618","article-title":"Classic and new animal models of Parkinson's disease","volume":"2012","author":"Blesa","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0080","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.nbd.2007.02.010","article-title":"Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease","volume":"26","author":"Boska","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb9000","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0091-3057(93)90520-4","article-title":"Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity","volume":"45","author":"Brodkin","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"14","key":"10.1016\/bs.pbr.2020.07.015_bb0090","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"80","author":"Burns","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2017.06.008","article-title":"Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence","volume":"123","author":"Cadoni","year":"2017","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.npp.1300033","article-title":"Inhibition of 5-HT neurotransmission increases clonidine protective effects on naloxone-induced conditioned place aversion in morphine-dependent rats","volume":"28","author":"Caill\u00e9","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/bs.pbr.2020.07.015_bb0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-007-0015-2","article-title":"Loss of thalamic serotonin transporters in early drug-na\u00efve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study","volume":"115","author":"Caretti","year":"2008","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fneur.2014.00078","article-title":"Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations","volume":"5","author":"Carta","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0115","series-title":"Clinical Trials in Parkinson's Disease","article-title":"Toxin-based rodent models of PD","author":"Cenci","year":"2020"},{"issue":"8","key":"10.1016\/bs.pbr.2020.07.015_bb0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00702-018-1886-0","article-title":"On the neuronal circuitry mediating L-DOPA-induced dyskinesia","volume":"125","author":"Cenci","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nucmedbio.2011.08.002","article-title":"Characterization of 4-[18F]-ADAM as an imaging agent for SERT in non-human primate brain using PET: a dynamic study","volume":"39","author":"Chen","year":"2012","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(87)90041-4","article-title":"Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"78","author":"Clarke","year":"1987","journal-title":"J. Neurol. Sci."},{"issue":"3\u20134","key":"10.1016\/bs.pbr.2020.07.015_bb0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-004-1788-8","article-title":"Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function","volume":"173","author":"Colado","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"14","key":"10.1016\/bs.pbr.2020.07.015_bb0140","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.25646","article-title":"MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice","volume":"28","author":"Costa","year":"2013","journal-title":"Mov. Disord."},{"issue":"Suppl. 3","key":"10.1016\/bs.pbr.2020.07.015_bb0145","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1017\/S0317167100037859","article-title":"MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms","volume":"14","author":"Crossman","year":"1987","journal-title":"Can. J. Neurol. Sci."},{"issue":"4741","key":"10.1016\/bs.pbr.2020.07.015_bb0150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1126\/science.3080808","article-title":"Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin","volume":"231","author":"D'Amato","year":"1986","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0155","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/sj.npp.1301225","article-title":"A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users","volume":"32","author":"de Win","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0160","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/brain\/awn255","article-title":"Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users","volume":"131","author":"de Win","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson's disease: development and distribution of \u03b1-synuclein pathology","volume":"42","author":"Del Tredici","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20076-y","article-title":"A meta-analysis of diffusion tensor imaging of substantia nigra in patients with Parkinson's disease","volume":"8","author":"Deng","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0175","first-page":"594","article-title":"Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes","volume":"258","author":"Di Monte","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3\u20134","key":"10.1016\/bs.pbr.2020.07.015_bb0180","first-page":"697","article-title":"Astrocytes as the site for bioactivation of neurotoxins","volume":"17","author":"Di Monte","year":"1996","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0185","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0006-8993(86)90782-1","article-title":"Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys","volume":"379","author":"Di Paolo","year":"1986","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"11C-WAY 100635 PET study. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2020.00025","article-title":"Neuropsychiatric disorders in Parkinson's disease: what do we know about the role of dopaminergic and non-dopaminergic systems?","volume":"14","author":"Dujardin","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0200","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0306-4522(86)90102-8","article-title":"Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys","volume":"18","author":"Eidelberg","year":"1986","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0306-4522(99)00437-6","article-title":"Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment","volume":"95","author":"Elsworth","year":"2000","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0210","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainresbull.2005.08.005","article-title":"Marmoset monkey models of Parkinson's disease: which model, when and why?","volume":"68","author":"Eslamboli","year":"2005","journal-title":"Brain Res. Bull."},{"issue":"Suppl. 1","key":"10.1016\/bs.pbr.2020.07.015_bb0215","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.parkreldis.2017.07.020","article-title":"The 200-year journey of Parkinson disease: reflecting on the past and looking towards the future","volume":"46","author":"Fahn","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0220","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease\u2014opportunities for novel therapeutics to reduce the problems of levodopa therapy","volume":"172","author":"Fox","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"issue":"6","key":"10.1016\/bs.pbr.2020.07.015_bb0230","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3174\/ajnr.A1556","article-title":"White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study","volume":"30","author":"Gattellaro","year":"2009","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"6","key":"10.1016\/bs.pbr.2020.07.015_bb0235","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ana.22423","article-title":"Therapies for dopaminergic-induced dyskinesias in Parkinson disease","volume":"69","author":"Gottwald","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0240","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0091-3057(91)90137-Q","article-title":"Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate","volume":"39","author":"Gough","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0245","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ejn.14094","article-title":"The clinical heterogeneity of Parkinson's disease and its therapeutic implications","volume":"49","author":"Greenland","year":"2019","journal-title":"Eur. J. Neurosci."},{"issue":"1\u20134","key":"10.1016\/bs.pbr.2020.07.015_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000098603","article-title":"Subthalamotomy improves MPTP-induced parkinsonism in monkeys","volume":"62","author":"Guridi","year":"1994","journal-title":"Stereotact. Funct. Neurosurg."},{"issue":"15","key":"10.1016\/bs.pbr.2020.07.015_bb0255","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0024-3205(86)90336-X","article-title":"\u201cIn vivo\u201d visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates","volume":"39","author":"Hantraye","year":"1986","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/bs.pbr.2020.07.015_bb0260","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1523\/JNEUROSCI.19-12-05096.1999","article-title":"Altered serotonin innervation patterns in the forebrain of monkeys treated with (+\/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery","volume":"19","author":"Hatzidimitriou","year":"1999","journal-title":"J. Neurosci."},{"issue":"1\u20132","key":"10.1016\/bs.pbr.2020.07.015_bb0265","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0304-3940(89)90351-0","article-title":"Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat","volume":"104","author":"Hekmatpanah","year":"1989","journal-title":"Neurosci. Lett."},{"issue":"10","key":"10.1016\/bs.pbr.2020.07.015_bb0270","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(99)00184-3","article-title":"Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey","volume":"96","author":"Imbert","year":"2000","journal-title":"J. Neurosci. Methods"},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0285","first-page":"713","article-title":"3,4-Methylenedioxymethamphetamine (\u201cecstasy\u201d) selectively destroys brain serotonin terminals in rhesus monkeys","volume":"249","author":"Insel","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/bs.pbr.2020.07.015_bb0290","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/mp.2011.50","article-title":"Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice","volume":"17","author":"Jacobsen","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0295","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/brain\/awx361","article-title":"Parkinson's disease tremors and serotonin","volume":"141","author":"Jankovic","year":"2018","journal-title":"Brain"},{"issue":"7","key":"10.1016\/bs.pbr.2020.07.015_bb0300","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","article-title":"Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity","volume":"82","author":"Javitch","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0305","first-page":"1","article-title":"Post mortem studies in Parkinson's disease\u2013is it possible to detect brain areas for specific symptoms?","volume":"56","author":"Jellinger","year":"1999","journal-title":"J. Neural Transm."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset","volume":"50","author":"Jenner","year":"1984","journal-title":"Neurosci. Lett."},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0315","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/mds.20223","article-title":"Ecstasy use-Parkinson's disease link tenuous","volume":"19","author":"Jerome","year":"2004","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0320","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3174\/ajnr.A0850","article-title":"Altered diffusion in the frontal lobe in Parkinson's disease","volume":"29","author":"Karagulle Kendi","year":"2008","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lfs.2014.02.010","article-title":"Elucidating the neurotoxic effects of MDMA and its analogs","volume":"101","author":"Karuppagounder","year":"2014","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0330","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mds.10643","article-title":"What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?","volume":"18","author":"Kish","year":"2003","journal-title":"Mov. Disord."},{"issue":"Pt. 1","key":"10.1016\/bs.pbr.2020.07.015_bb0335","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"issue":"Pt. 6","key":"10.1016\/bs.pbr.2020.07.015_bb0340","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/brain\/awq103","article-title":"Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography\/[(11)C]DASB and structural brain imaging study","volume":"133","author":"Kish","year":"2010","journal-title":"Brain"},{"issue":"1\u20133","key":"10.1016\/bs.pbr.2020.07.015_bb0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2009.12.010","article-title":"Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons","volume":"629","author":"Kittler","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0350","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuroscience.2010.03.018","article-title":"MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation","volume":"168","author":"Kivell","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2012.08.015","article-title":"6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats","volume":"1477","author":"Kolasiewicz","year":"2012","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0360","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1056\/NEJMc030208","article-title":"MDMA and parkinsonism","volume":"349","author":"Kuniyoshi","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"s1","key":"10.1016\/bs.pbr.2020.07.015_bb0365","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3233\/JPD-179006","article-title":"The MPTP story","volume":"7","author":"Langston","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0370","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","article-title":"Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey","volume":"292","author":"Langston","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0375","doi-asserted-by":"crossref","first-page":"e1876","DOI":"10.1212\/WNL.0000000000009363","article-title":"Abnormalities in the white matter tracts in patients with Parkinson disease and psychosis","volume":"94","author":"Lenka","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0380","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1073\/pnas.79.20.6385","article-title":"Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons","volume":"79","author":"Levitt","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1148\/radiol.11101918","article-title":"Potential long-term effects of MDMA on the basal ganglia-thalamocortical circuit: a proton MR spectroscopy and diffusion-tensor imaging study","volume":"260","author":"Liu","year":"2011","journal-title":"Radiology"},{"issue":"Pt. 9","key":"10.1016\/bs.pbr.2020.07.015_bb0390","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"issue":"7","key":"10.1016\/bs.pbr.2020.07.015_bb0395","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cercor\/bhp236","article-title":"Opposing effects of 5,7-DHT infusions into the orbitofrontal cortex and amygdala on flexible responding","volume":"20","author":"Man","year":"2010","journal-title":"Cereb. Cortex"},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0400","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00702-017-1774-z","article-title":"Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease","volume":"125","author":"Masilamoni","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0405","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.irn.2018.09.003","article-title":"PET molecular imaging in familial Parkinson's disease","volume":"142","author":"Matarazzo","year":"2018","journal-title":"Int. Rev. Neurobiol."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0410","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/mds.27201","article-title":"Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey","volume":"33","author":"M\u00e9t\u00e9reau","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0415","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding dopaminergic cell death pathways in Parkinson disease","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104643","article-title":"Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys","volume":"134","author":"Millot","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"18","key":"10.1016\/bs.pbr.2020.07.015_bb0425","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM199905063401817","article-title":"Parkinsonism after taking ecstasy","volume":"340","author":"Mintzer","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0430","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/bs.pbr.2020.07.015_bb0435","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/00952990701651564","article-title":"Diffusion tensor imaging in MDMA users and controls: association with decision making","volume":"33","author":"Moeller","year":"2007","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0440","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pneurobio.2015.09.011","article-title":"Amphetamine-related drugs neurotoxicity in humans and in experimental animals: main mechanisms","volume":"155","author":"Moratalla","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0445","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neubiorev.2018.11.004","article-title":"Neuroimaging of chronic MDMA (\u201cecstasy\u201d) effects: a meta-analysis","volume":"96","author":"M\u00fcller","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0450","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0455","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nbd.2010.11.007","article-title":"Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease","volume":"41","author":"Navailles","year":"2011","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/bs.pbr.2020.07.015_bb0460","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1002\/hbm.23324","article-title":"Characterizing structural neural networks in de novo Parkinson's disease patients using diffusion tensor imaging","volume":"37","author":"Nigro","year":"2016","journal-title":"Hum. Brain Mapp."},{"issue":"9","key":"10.1016\/bs.pbr.2020.07.015_bb0465","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0470","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/mds.10623","article-title":"Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs","volume":"18","author":"O'Suilleabhain","year":"2003","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0475","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7861\/clinmedicine.16-4-371","article-title":"Imaging in Parkinson's disease","volume":"16","author":"Pagano","year":"2016","journal-title":"Clin. Med. (Lond.)"},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0480","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.24859","article-title":"Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies","volume":"81","author":"Pagano","year":"2017","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0485","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jchemneu.2011.04.005","article-title":"Serotonin innervation of basal ganglia in monkeys and humans","volume":"41","author":"Parent","year":"2011","journal-title":"J. Chem. Neuroanat."},{"issue":"6","key":"10.1016\/bs.pbr.2020.07.015_bb0490","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","article-title":"The neuropathologic basis of different clinical subgroups of Parkinson's disease","volume":"50","author":"Paulus","year":"1991","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0495","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain"},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0500","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1093\/brain\/awq212","article-title":"Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature","volume":"133","author":"P\u00e9ran","year":"2010","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0505","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0006-8993(91)91444-6","article-title":"Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset","volume":"567","author":"Perez-Otano","year":"1991","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0510","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jnr.20730","article-title":"Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins","volume":"83","author":"Petzinger","year":"2006","journal-title":"J. Neurosci. Res."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0515","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0306-4522(91)90080-8","article-title":"Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey","volume":"44","author":"Pifl","year":"1991","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0520","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3174\/ajnr.A3178","article-title":"Thalamic projection fiber integrity in de novo Parkinson's disease","volume":"34","author":"Planetta","year":"2013","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0525","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0530","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: from research setting to clinical practice","volume":"10","author":"Politis","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"38","key":"10.1016\/bs.pbr.2020.07.015_bb9005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000976","article-title":"Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants","volume":"2","author":"Politis","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0535","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","article-title":"Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin\/dopamine transporter ratio","volume":"26","author":"Politis","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0540","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0545","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009308","article-title":"Modeling Parkinson's disease in primates: the MPTP model","volume":"2","author":"Porras","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/bs.pbr.2020.07.015_bb0550","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mds.27670","article-title":"Prodromal Parkinson's disease: the decade past, the decade to come","volume":"34","author":"Postuma","year":"2019","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0555","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/mds.27793","article-title":"Early limbic microstructural alterations in apathy and depression in de novo Parkinson's disease","volume":"34","author":"Prange","year":"2019","journal-title":"Mov. Disord."},{"issue":"Pt. 10","key":"10.1016\/bs.pbr.2020.07.015_bb0560","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/brain\/awv215","article-title":"Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease","volume":"138","author":"Qamhawi","year":"2015","journal-title":"Brain"},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0565","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.36.4.556","article-title":"Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen","volume":"36","author":"Raisman","year":"1986","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0570","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/syn.10130","article-title":"Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity","volume":"46","author":"Reneman","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0575","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1988.03410010059035","article-title":"(+\/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates","volume":"260","author":"Ricaurte","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/bs.pbr.2020.07.015_bb0580","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neubiorev.2016.02.003","article-title":"Meta-analysis of molecular imaging of serotonin transporters in ecstasy\/polydrug users","volume":"63","author":"Roberts","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0585","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of \u201cecstasy\u201d [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/bs.pbr.2020.07.015_bb0590","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/mds.27205","article-title":"Structural abnormality of substantia nigra induced by methamphetamine abuse","volume":"32","author":"Rumpf","year":"2017","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/bs.pbr.2020.07.015_bb0595","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0600","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res."},{"issue":"Pt. 10","key":"10.1016\/bs.pbr.2020.07.015_bb0605","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/brain\/awt234","article-title":"Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease","volume":"136","author":"Scherfler","year":"2013","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/bs.pbr.2020.07.015_bb0610","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(90)90245-2","article-title":"Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine","volume":"181","author":"Schmidt","year":"1990","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0615","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0091-3057(89)90372-9","article-title":"Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage","volume":"34","author":"Schneider","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0620","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-N","article-title":"Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys","volume":"519","author":"Schneider","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0625","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/1055-8330(95)90014-4","article-title":"Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey","volume":"4","author":"Schneider","year":"1995","journal-title":"Neurodegeneration"},{"issue":"8","key":"10.1016\/bs.pbr.2020.07.015_bb0630","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00702-018-1871-7","article-title":"Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers","volume":"125","author":"Sgambato","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0635","first-page":"79","article-title":"Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine","volume":"247","author":"Stone","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/bs.pbr.2020.07.015_bb0640","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/mdc3.12673","article-title":"Imaging markers of progression in Parkinson's disease","volume":"5","author":"Strafella","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0645","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0650","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2191-219X-3-44","article-title":"SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias","volume":"3","author":"Suwijn","year":"2013","journal-title":"EJNMMI Res."},{"key":"10.1016\/bs.pbr.2020.07.015_bb0655","first-page":"78","article-title":"Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions","volume":"43","author":"Szabo","year":"2002","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/bs.pbr.2020.07.015_bb0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056438","article-title":"Illicit stimulant use is associated with abnormal substantia nigra morphology in humans","volume":"8","author":"Todd","year":"2013","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/bs.pbr.2020.07.015_bb0665","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1212\/01.wnl.0000340982.01727.6e","article-title":"High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson's disease","volume":"72","author":"Vaillancourt","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0670","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"19\u201320","key":"10.1016\/bs.pbr.2020.07.015_bb0675","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s00213-016-4396-5","article-title":"The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies","volume":"233","author":"Vegting","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/bs.pbr.2020.07.015_bb0680","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","article-title":"\u03b1-Synuclein-based animal models of parkinson's disease: challenges and opportunities in a new era","volume":"39","author":"Visanji","year":"2016","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/bs.pbr.2020.07.015_bb0685","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.psyneuen.2010.12.012","article-title":"Tryptophan hydroxylase-2 (TPH2) in disorders of cognitive control and emotion regulation: a perspective","volume":"36","author":"Waider","year":"2011","journal-title":"Psychoneuroendocrinology"},{"issue":"4722","key":"10.1016\/bs.pbr.2020.07.015_bb0690","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.3875898","article-title":"Distinct monoamine oxidase A and B populations in primate brain","volume":"230","author":"Westlund","year":"1985","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.pbr.2020.07.015_bb0695","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1474-4422(17)30056-X","article-title":"Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies","volume":"16","author":"Wile","year":"2017","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/bs.pbr.2020.07.015_bb0700","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1474-4422(19)30140-1","article-title":"Serotonergic pathology and disease burden in the premotor and motor phase of A53T \u03b1-synuclein parkinsonism: a cross-sectional study","volume":"18","author":"Wilson","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0705","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3988\/jcn.2015.11.1.42","article-title":"Whole-brain diffusion-tensor changes in parkinsonian patients with impulse control disorders","volume":"11","author":"Yoo","year":"2015","journal-title":"J. Clin. Neurol."},{"issue":"4","key":"10.1016\/bs.pbr.2020.07.015_bb0710","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5625\/lar.2015.31.4.155","article-title":"Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care","volume":"31","author":"Yun","year":"2015","journal-title":"Lab. Anim. Res."},{"issue":"8","key":"10.1016\/bs.pbr.2020.07.015_bb0715","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: a review","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/bs.pbr.2020.07.015_bb0720","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23917","article-title":"Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging","volume":"27","author":"Zhan","year":"2012","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/bs.pbr.2020.07.015_bb0725","first-page":"480","article-title":"Combining diffusion tensor imaging and susceptibility weighted imaging on the substantia nigra of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced rhesus monkey model of Parkinson's disease","volume":"64","author":"Zhang","year":"2015","journal-title":"West Indian Med. J."},{"issue":"27","key":"10.1016\/bs.pbr.2020.07.015_bb0730","first-page":"2548","article-title":"Why psychosis is frequently associated with Parkinson's disease?","volume":"8","author":"Zhong","year":"2013","journal-title":"Neural Regen. Res."}],"container-title":["Progress in Brain Research","5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320301138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320301138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:08:12Z","timestamp":1738170492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612320301138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780444642585"],"references-count":147,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2020.07.015","relation":{},"ISSN":["0079-6123"],"issn-type":[{"type":"print","value":"0079-6123"}],"subject":[],"published":{"date-parts":[[2021]]}}}